TY  - JOUR
AU  - Spittel, Susanne
AU  - Grehl, Torsten
AU  - Weydt, Patrick
AU  - Kettemann, Dagmar
AU  - Fabian, Rachel
AU  - Rödiger, Annekathrin
AU  - Smesny, Uta
AU  - Steinbach, Robert
AU  - Ilse, Benjamin
AU  - Weyen, Ute
AU  - Petri, Susanne
AU  - Lumi, Rea
AU  - Bjelica, Bogdan
AU  - Lingor, Paul
AU  - Grosskreutz, Julian
AU  - Göricke, Bettina M
AU  - Pfeilschifter, Waltraud
AU  - Schmeja, Wibke
AU  - Dorst, Johannes
AU  - Mensch, Alexander
AU  - Siebert, Jürgen
AU  - Norden, Jenny
AU  - Bernsen, Sarah
AU  - Subramanian, Senthil Kumar
AU  - Hildebrandt, Barbara
AU  - Walter, Bertram
AU  - Münch, Christoph
AU  - Maier, André
AU  - Meyer, Thomas
TI  - Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter study.
JO  - Amyotrophic lateral sclerosis & frontotemporal degeneration
VL  - 27
IS  - 1-2
SN  - 2167-8421
CY  - Abingdon
PB  - Taylor Francis Group
M1  - DZNE-2026-00157
SP  - 185 - 197
PY  - 2026
AB  - In amyotrophic lateral sclerosis (ALS), dextromethorphan/quinidine (DMQ) has been reported to reduce bulbar symptoms, including dysarthria and dysphagia. However, data on patients' perceptions of DMQ treatment are limited.Data on DMQ treatment were collected from 1065 ALS patients treated at 13 ALS centers between 10-2015 and 06-2025. Patient-reported outcome measures (PROM) of 179 participants were remotely assessed via the 'ALS App'. PROM included the self-explanatory version of the ALS Functional Rating Scale (ALSFRS-R-SE), the Net Promoter Score (NPS); and Treatment Satisfaction Questionnaire for Medication (TSQM-9).Mean disease duration was 29.3 months (SD 38.1). ALS progression before treatment was 0.82 points/month (ALSFRS-R). Mean DMQ treatment duration was 8.4 months (SD 10.8), including 35.2
KW  - Humans
KW  - Dextromethorphan: therapeutic use
KW  - Amyotrophic Lateral Sclerosis: drug therapy
KW  - Amyotrophic Lateral Sclerosis: complications
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Quinidine: therapeutic use
KW  - Aged
KW  - Patient Reported Outcome Measures
KW  - Drug Combinations
KW  - Treatment Outcome
KW  - Patient Satisfaction
KW  - Adult
KW  - Amyotrophic lateral sclerosis (Other)
KW  - bulbar symptoms (Other)
KW  - dextromethorphan/quinidine (DMQ) (Other)
KW  - dysarthria (Other)
KW  - dysphagia (Other)
KW  - patient-reported outcomes (Other)
KW  - Dextromethorphan (NLM Chemicals)
KW  - Quinidine (NLM Chemicals)
KW  - dextromethorphan - quinidine combination (NLM Chemicals)
KW  - Drug Combinations (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40932199
DO  - DOI:10.1080/21678421.2025.2557932
UR  - https://pub.dzne.de/record/285032
ER  -